Details of the Drug Pharmacogenomic Perturbation Atlas

Miglustat Drug Info

BuDNJ; Butyldeoxynojirimycin; Miglustatum; NBV; Vevesca; Zavesca; Miglustat [USAN]; OGT 918; SC 48334; SC48334; Miglustat, Hydrochloride; N-Butyl deoxynojirimycin; N-Butyl dnj; N-Butyldeoxynojirimycin; N-Butylmoranoline; NB-DNJ; OGT-918; SC-48334; Zavesca (TN); Miglustat (USAN/INN); N-Bu-DNJ; N-Butyl-DNJ; N-Butyl-deoxynojirimycin; N-(n-Butyl)deoxynojirimycin; N-butyl-1-deoxynojirimycin; N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol; (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Dideoxy-1,5-N-butylimino-D-glucitol

Therapeutic Class

Anti-HIV Agents

Cross-matching ID

PubChem CID

51634

ChEBI ID

CHEMBL1029

CAS Number

CAS 72599-27-0

TTD Drug ID

D0HR8Z

ACDINA Drug ID

D00434

General Information of Drug (ID: DM5J64S)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Malaria	-1.76	4.97e-2	44/50 (88%)	IL6;GYPA;ICAM1;...
NF-kappa B signaling pathway	-1.82	3.10e-2	90/104 (86.54%)	TRAF1;ICAM1;NFKBIA;...
Steroid hormone biosynthesis	-1.84	2.83e-2	43/61 (70.49%)	CYP19A1;CYP1A2;HSD17B12;...
Lipid and atherosclerosis	-1.87	2.52e-2	190/215 (88.37%)	ATF6;HSPA1A;MAPK13;...
Inflammatory bowel disease	-1.87	2.66e-2	58/65 (89.23%)	STAT6;RELA;TGFB2;...
PPAR signaling pathway	-1.91	1.95e-2	66/74 (89.19%)	SCP2;ACOX1;ACOX2;...
Metabolism of xenobiotics by cytochrome P450	-1.93	2.05e-2	49/77 (63.64%)	ALDH3A1;CYP1A1;GSTK1;...
Legionellosis	-2.11	3.99e-3	51/57 (89.47%)	HSPA1A;IL18;TNF;...
Viral protein interaction with cytokine and cytokine re...	-2.13	4.79e-3	84/100 (84%)	TNFRSF10C;CCL4;IL10;...
IL-17 signaling pathway	-2.14	5.99e-3	84/94 (89.36%)	MAPK13;TNF;CXCL6;...
Rheumatoid arthritis	-2.15	3.99e-3	78/93 (83.87%)	IL18;TNF;IL15;...
Toll-like receptor signaling pathway	-2.25	0.00e+0	94/104 (90.38%)	CD80;IFNAR2;IRF5;...
TNF signaling pathway	-2.31	0.00e+0	103/112 (91.96%)	MAPK13;TNF;FAS;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 2.22uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 2.22uM	24H

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	15uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 2.22uM	24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 2.22uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 2.22uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H